BioMarin Pharma (BMRN) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.44 -1.83%
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Weighted average common shares outstanding, diluted: 167.71M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $766 million versus the consensus estimate of $755.94 million.
GUIDANCE:
BioMarin Pharma sees FY2026 EPS of $4.85-$5.05, versus the consensus of $4.64. BioMarin Pharma sees FY2026 revenue of $3.83-3.93 million, versus the consensus of $3.83 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calix, Inc. (CALX) Tops Q3 EPS by 3c; offers guidance
- EverQuote (EVER) Tops Q3 EPS by 2c; Offers Guidance
- Ryman Hospitality Properties (RHP) Tops Q3 EPS by 15c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
